"Antisickling Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
| Descriptor ID |
D000986
|
| MeSH Number(s) |
D27.505.954.502.135
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antisickling Agents".
Below are MeSH descriptors whose meaning is more specific than "Antisickling Agents".
This graph shows the total number of publications written about "Antisickling Agents" by people in this website by year, and whether "Antisickling Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 4 | 0 | 4 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antisickling Agents" by people in Profiles.
-
Jabour SM, Beachy S, Coburn S, Lanzkron S, Eakin MN. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease. J Racial Ethn Health Disparities. 2019 12; 6(6):1233-1243.
-
Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19; 379(3):226-235.
-
Hayes MM, Vedamurthy A, George G, Dweik R, Klings ES, Machado RF, Gladwin MT, Wilson KC, Thomson CC. Pulmonary hypertension in sickle cell disease. Ann Am Thorac Soc. 2014 Nov; 11(9):1488-9.
-
Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev. 2012; 7:CD003426.
-
Haywood C, Beach MC, Bediako S, Carroll CP, Lattimer L, Jarrett D, Lanzkron S. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2011 Jan; 86(1):85-7.
-
Lanzkron S, Haywood C, Fagan PJ, Rand CS. Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved. 2010 Feb; 21(1):277-86.
-
Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev. 2010; (1):CD003426.
-
Haywood C, Beach MC, Lanzkron S, Strouse JJ, Wilson R, Park H, Witkop C, Bass EB, Segal JB. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc. 2009 Oct; 101(10):1022-33.
-
Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008 Dec; 122(6):1332-42.
-
Lanzkron S, Haywood C, Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008 Aug; 100(8):968-73.